KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $28.7 million.

  • Alnylam Pharmaceuticals' Interest & Investment Income fell 1077.89% to $28.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.9 million, marking a year-over-year decrease of 454.77%. This contributed to the annual value of $122.0 million for FY2024, which is 2765.88% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Interest & Investment Income is $28.7 million, which was down 1077.89% from $27.5 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Interest & Investment Income registered a high of $32.1 million during Q3 2024, and its lowest value of $225000.0 during Q3 2021.
  • For the 5-year period, Alnylam Pharmaceuticals' Interest & Investment Income averaged around $17.3 million, with its median value being $21.1 million (2023).
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Interest & Investment Income crashed by 9178.83% in 2021, and later skyrocketed by 337555.56% in 2022.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Interest & Investment Income stood at $495000.0 in 2021, then skyrocketed by 2743.84% to $14.1 million in 2022, then skyrocketed by 116.0% to $30.4 million in 2023, then rose by 2.02% to $31.0 million in 2024, then fell by 7.54% to $28.7 million in 2025.
  • Its Interest & Investment Income stands at $28.7 million for Q3 2025, versus $27.5 million for Q2 2025 and $28.7 million for Q1 2025.